Immunopathogenic events in the acute infection of rhesus monkeys with SIVmac.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Immunopathogenic events in the acute infection of rhesus monkeys with SIVmac.

Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 18. Unique Identifier : AIDSLINE PRIM11/94191610
Reimann KA; Yasutomi Y; Lin W; Tenner-Racz K; Racz P; Letvin NL; New England Regional Primate Research Center, Harvard Medical; School, Southborough, MA 01772.

Abstract: Infection of the rhesus monkey with SIVmac was employed to explore the early immune events associated with the initial containment of an acute AIDS virus infection. In 9 rhesus monkeys infected intravenously with uncloned SIVmac251, p27 antigenemia was usually detected transiently from approximately day 7 through day 21 following virus inoculation. SIVmac replication in lymph nodes measured by in situ RNA hybridization closely paralleled the magnitude of viremia. The containment of SIVmac spread by 28 days following infection suggests an efficient, early immune control of this virus infection. Anti-SIVmac antibodies were first detected at approximately day 14 and were high titer at the time antigenemia was cleared. A rise in circulating and lymph node CD8+ T cells occurred coincident with the clearance of antigenemia and persisted thereafter. These CD8+ lymphocytes in lymph node had increased expression of both MHC class II and the adhesion molecule LFA-1; they also demonstrated decreased expression of the naive T cell-associated CD45RA molecule. SIVmac-specific cytotoxic T lymphocyte precursors were detected both in blood and lymph node by 7 days post-virus inoculation. These studies indicate that both virus-specific humoral and cellular immune mechanisms in blood and lymph node are associated with the clearance of viremia that occurs in within the first month of infection of rhesus monkeys with SIVmac.

Keywords: Animal Antigens, CD8/ANALYSIS Antigens, Viral/ADMINISTRATION & DOSAGE Histocompatibility Antigens Class II/ANALYSIS/BIOSYNTHESIS In Situ Hybridization Lymph Nodes/*MICROBIOLOGY/PATHOLOGY Lymphocyte Function-Associated Antigen-1/ANALYSIS/BIOSYNTHESIS Macaca mulatta RNA, Viral/ANALYSIS Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/*PATHOLOGY *SIV/PHYSIOLOGY T-Lymphocyte Subsets/PATHOLOGY Time Factors Viremia/IMMUNOLOGY/PATHOLOGY Virus Replication ABSTRACT
940730
M9470908

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .